Should we be acquiring Alphabet or Protalix Biotherapeutics?


USD 1.05  0.01  0.96%   

It looks like Alphabet will be up for a correction way faster as its share price whent up 2.39% today to Protalix Biotherapeutics's 1.6529%. As many rational traders are trying to avoid healthcare space, it makes sense to break down Protalix Biotherapeutics a little further and understand how it stands against Alphabet and other similar entities. We are going to inspect some of the competitive aspects of both Protalix and Alphabet.
Published over a month ago
View all stories for Protalix Biotherapeutics | View All Stories
By analyzing existing essential indicators between Protalix Biotherapeutics and Alphabet, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Alphabet with a short position in Protalix Biotherapeutics. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Protalix Biotherapeutics has an asset utilization ratio of 61.19 percent. This suggests that the company is making $0.61 for each dollar of assets. An increasing asset utilization means that Protalix Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Protalix or Hermes is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Protalix Biotherapeutics's Liquidity

Protalix Biotherapeutics financial leverage refers to using borrowed capital as a funding source to finance Protalix Biotherapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Protalix Biotherapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Protalix Biotherapeutics's total debt and its cash.

Correlation Between Protalix and Hermes Intl SA

In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Protalix Biotherapeutics together with similar or unrelated positions with a negative correlation. For example, you can also add Hermes Intl to your portfolio. If Hermes Intl is not perfectly correlated to Protalix Biotherapeutics it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Protalix Biotherapeutics, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between PLX and HESAF for more information.

Sale by Akirov Alfred of 1898 shares of Protalix Biotherapeutics

Legal trades by Protalix Biotherapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Protalix insider trading alert for sale of common stock by Akirov Alfred, the corporate stakeholder, on 20th of September 2022. This event was filed by Protalix Biotherapeutics with SEC on 2013-03-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Protalix Biotherapeutics

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Protalix Biotherapeutics revenue. Based on the latest financial disclosure, Protalix Biotherapeutics reported 43.12 M of revenue. This is 99.43% lower than that of the Healthcare sector and 94.2% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.54% higher than that of Protalix Biotherapeutics. As for Alphabet we see revenue of 278.14 B, which is much higher than that of the Biotechnology

278.1 B
PLX43.12 Million0.0155
Sector742.91 Million0.27
GOOGL278.14 Billion99.72

Momentum Analysis of Protalix Biotherapeutics suggests possible reversal in September

Current Skewness is up to 0.05. Price may slide again.
As of the 14th of August 2022, Protalix Biotherapeutics holds the Coefficient Of Variation of 758.85, semi deviation of 1.77, and Risk Adjusted Performance of 0.1694. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protalix Biotherapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Protalix Biotherapeutics, which can be compared to its competitors. Please check Protalix Biotherapeutics variance and potential upside to decide if Protalix Biotherapeutics is priced some-what accurately, providing market reflects its current price of 1.23 per share. Given that Protalix Biotherapeutics is a hitting penny stock territory we advise to closely look at its total risk alpha.

The Current Takeaway on Protalix Biotherapeutics Investment

While many of the other players under the biotechnology industry are still a bit expensive, Protalix Biotherapeutics may offer a potential longer-term growth to investors. With an optimistic outlook on your 90 days horizon, it may be a good time to pick up new shares of Protalix or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Protalix Biotherapeutics.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Protalix Biotherapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to